U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Silver

    23.14
    -0.40 (-1.70%)
     
  • EUR/USD

    1.1322
    +0.0110 (+0.99%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3342
    +0.0022 (+0.16%)
     
  • USD/JPY

    113.2600
    -2.0790 (-1.80%)
     
  • BTC-USD

    55,204.11
    +662.54 (+1.21%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.66 (-2.53%)
     

Atea Pharmaceuticals stock rocked after disappointing trial results of SARS-CoV-2 pill

·1 min read
Atea Pharmaceuticals stock rocked after disappointing trial results of SARS-CoV-2 pill
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Atea Pharmaceuticals Inc. took a 70.7% nosedive on heavy volume toward a record low in morning trading Tuesday, after the biopharmaceutical company said a Phase 2 trial of its oral treatment of SARS-CoV-2 virus in an outpatient setting failed to meet its primary endpoint. Trading volume swelled to 21.6 million shares, compared with the full-day average of about 2.7 million shares. The company said primary endpoint of the AT-527 study was a reduction from baseline of SARS-CoV-2 in patie